Bone Therapeutics S.A. Stock
Your prediction
Bone Therapeutics S.A. Stock
Pros and Cons of Bone Therapeutics S.A. in the next few years
Pros
Cons
Performance of Bone Therapeutics S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bone Therapeutics S.A. | -11.690% | -3.750% | -45.000% | -89.895% | -90.375% | -99.692% | -99.792% |
| CorMedix Inc | 3.910% | -1.220% | 27.225% | 10.455% | 42.105% | -31.064% | -30.532% |
| TherapeuticsMD Inc. | 1.170% | -1.156% | -18.571% | -47.546% | -18.571% | -96.381% | -99.103% |
| Mayne Pharma Group Ltd. | - | 0.000% | -3.211% | 67.460% | 12.234% | 1629.508% | 839.866% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When analyzing the financials of Bone Therap, a company in the Pharmaceuticals industry, it is apparent that the company has some significant challenges to overcome. However, it also possesses unique strengths, providing some opportunities for potential investors.
Net Receivables: Bone Therap seems to have a healthy amount of net receivables, which indicates the company's effectiveness in dealing with its customers and debtors. Net receivables have increased from €2.58 million in 2021 to €3.84 million in 2022.
Increase in Cash: The company experienced a considerable increase in cash between 2020 and 2021, growing from €9.51 million to €18.46 million. This is an excellent sign of a company's financial health and ability to cover short-term obligations.